It is widely used in emergency care, neurology, and hospital medicine, making it a strong critical care and nutritional injectable segment product
In SPMS, characterized by steady deterioration without acute attacks, treatment strategies often involve continuing or altering DMT used during the earlier RRMS phase, such as interferon beta, or considering immune-modulating agents, such as methotrexate, cyclophosphamide, or glucocorticoid pulses [142, 143]
Inject once weekly as directed by your healthcare provider using a vial and syringe
Archived (PDF) from the original on 8 August 2016
Updated Guidance on the Use of Multidose Vials (PIDAC IPC Guidance)
Shelf life is supplier-specific and formulation-dependent